Watt Alan P相关文献与解析，生知库 | 链接生命科学的每一步

Ester Prodrug NLRP3 Inflammasome Inhibitor NT-0796 is Brain Active due to Activation by Local Expression of Carboxylesterase-1

酯类前药 NLRP3 炎症小体抑制剂 NT-0796 因羧酸酯酶-1 的局部表达而被激活，从而具有脑活性。

Digby, Zsofia; Diamond, Christine; Wescott, Heather; Smolak, Pam; Thornton, Peter; Lindsay, Nicola; Gabel, Christopher A; Clarke, Nicholas; Watt, Alan P

炎症

Anti-Neuroinflammatory and Anti-Inflammatory Effects of the NLRP3 Inhibitor NT-0796 in Subjects with Parkinson's Disease

NLRP3抑制剂NT-0796在帕金森病患者中的抗神经炎症和抗炎作用

期刊:Movement Disorders

影响因子:7.6

doi:10.1002/mds.30307

Clarke, Nicholas; Thornton, Peter; Reader, Valérie; Lindsay, Nicola; Digby, Zsofia; Mullen, Bianca; Gorman, Michelle; Jacobson, Eric; Langdon, Grant; Johnstone, Hilary; Wheeler, Alistair; Watt, Alan P

Profile of NT-0527, a brain penetrant NLRP3 Inflammasome inhibitor suitable as an in vivo tool compound for neuroinflammatory disorders.

NT-0527 是一种可穿透血脑屏障的 NLRP3 炎症小体抑制剂，适用于作为神经炎症性疾病的体内治疗药物

期刊:RSC Medicinal Chemistry

影响因子:3.6

doi:10.1039/d5md00639b

Harrison David, Billinton Andy, Bock Mark G, Clarke Nicholas P, Digby Zsofia, Gabel Christopher A, Lindsay Nicola, Reader ValÃ©rie, Scanlon Jane, Smolak Pamela, Thornton Peter, Wescott Heather, Watt Alan P

The NLRP3 inhibitor NT-0796 enhances and sustains GLP-1R agonist-mediated weight loss in a murine diet-induced obesity model

NLRP3抑制剂NT-0796可增强并维持GLP-1R激动剂介导的小鼠饮食诱导肥胖模型中的体重减轻。

期刊:

影响因子:

doi:10.1002/oby.24305

Thornton, Peter; Reader, Valérie; Digby, Zsofia; Doedens, John; Lindsay, Nicola; Clarke, Nicholas; Watt, Alan P

Pharmacological Analysis of NLRP3 Inflammasome Inhibitor Sodium [(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl][(1-methyl-1H-pyrazol-4-yl)({[(2S)-oxolan-2-yl]methyl})sulfamoyl]azanide in Cellular and Mouse Models of Inflammation Provides a Translational Framework.

在细胞和小鼠炎症模型中对 NLRP3 炎症小体抑制剂钠 [(1,2,3,5,6,7-六氢-s-茚满-4-基)氨基甲酰基][(1-甲基-1H-吡唑-4-基)({[(2S)-氧杂环戊烷-2-基]甲基})磺酰胺酰基]氮化物进行药理学分析，为转化应用提供了框架

期刊:ACS Pharmacology and Translational Science

影响因子:3.7

doi:10.1021/acsptsci.4c00061

Doedens John R, Smolak Pamela, Nguyen MyTrang, Wescott Heather, Diamond Christine, Schooley Ken, Billinton Andy, Harrison David, Koller Beverly H, Watt Alan P, Gabel Christopher A

CNS-targeted NLRP3 Inhibition by NT-0527 confers therapeutic advantage in a CAPS mouse model.

NT-0527 对 CNS 靶向 NLRP3 的抑制作用在 CAPS 小鼠模型中具有治疗优势。

Ester Prodrug NLRP3 Inflammasome Inhibitor NT-0796 is Brain Active due to Activation by Local Expression of Carboxylesterase-1

酯类前药 NLRP3 炎症小体抑制剂 NT-0796 因羧酸酯酶-1 的局部表达而被激活，从而具有脑活性。

Anti-Neuroinflammatory and Anti-Inflammatory Effects of the NLRP3 Inhibitor NT-0796 in Subjects with Parkinson's Disease

NLRP3抑制剂NT-0796在帕金森病患者中的抗神经炎症和抗炎作用

Profile of NT-0527, a brain penetrant NLRP3 Inflammasome inhibitor suitable as an in vivo tool compound for neuroinflammatory disorders.

NT-0527 是一种可穿透血脑屏障的 NLRP3 炎症小体抑制剂，适用于作为神经炎症性疾病的体内治疗药物

The NLRP3 inhibitor NT-0796 enhances and sustains GLP-1R agonist-mediated weight loss in a murine diet-induced obesity model

NLRP3抑制剂NT-0796可增强并维持GLP-1R激动剂介导的小鼠饮食诱导肥胖模型中的体重减轻。

Pharmacological Analysis of NLRP3 Inflammasome Inhibitor Sodium [(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl][(1-methyl-1H-pyrazol-4-yl)({[(2S)-oxolan-2-yl]methyl})sulfamoyl]azanide in Cellular and Mouse Models of Inflammation Provides a Translational Framework.

在细胞和小鼠炎症模型中对 NLRP3 炎症小体抑制剂钠 [(1,2,3,5,6,7-六氢-s-茚满-4-基)氨基甲酰基][(1-甲基-1H-吡唑-4-基)({[(2S)-氧杂环戊烷-2-基]甲基})磺酰胺酰基]氮化物进行药理学分析，为转化应用提供了框架